Up to 1 billion yuan!

Just now, CSPC and Corning Jereh jointly announced that the two companies have entered into a license agreement for the HER2 bispecific antibody independently developed by Corning Jereh

According to the terms of the license agreement, Sinopharm Group subsidiary Jinmante Biotechnology will obtain KN026 as a single drug and a combination of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) for the treatment of breast cancer and The exclusive development and commercialization license rights for gastric cancer indications , all costs and expenses of clinical development activities are borne by him, and he becomes the holder of the marketing license of KN026 in Mainland China

Corning Jereh has the right to receive up to RMB 1 billion in advance and milestone payments , including an advance payment of RMB150 million , and a development milestone payment of no more than RMB 450 million based on the development progress ofKN026.

KN026 is a bispecific antibody drug targeting HER2 with independent intellectual property rights developed by Jiangsu Corning Jereh.

According to the Insight database, KN026 currently has 4 clinical registrations registered in China , 3 of which have progressed to clinical stage 2, respectively for HER2-positive advanced gastric and gastroesophageal junction cancer , HER2 low expression or HER2-positive recurrent/metastatic breast cancer , andNeoadjuvant therapy for HER2-positive early or locally advanced breast cancer

From the Insight database (http://db.

Two domestic double antibodies with the same target have entered clinical trials, namely Zanidatamab (ZW-25) cooperating with BeiGene and Zymeworks , and MBS301 from Tianguangshi .